A new test for bleeding between mother and baby during pregnancy
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy, Women’s health & pregnancy clinical trials.
This study is looking at a new way to detect bleeding between the mother and baby during pregnancy (called fetomaternal hemorrhage), which can lead to a blood problem in the newborn called hemolytic disease. The goal is to see if this test can help diagnose the condition earlier and hopefully improve care for the baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 weeks or more along in your pregnancy.
- You have at least one of these risk factors: a recent belly injury, a prenatal procedure (like amniocentesis), a pregnancy complication (like placental abruption or preeclampsia), or a baby with signs of anemia or growth problems.
- You have a blood type mismatch with your baby (like Rh-negative) or a positive antibody test early in pregnancy.
- You do not have severe blood or immune system disorders (like clotting problems or autoimmune disease).
- You are willing to have your baby's blood and other samples checked after birth to see if the test works.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new blood test that can screen for genetic problems in babies during pregnancy. It may find more conditions than standard tests, especially for pregnancies with certain ultrasound findings or other risk factors.
This study tracks pregnancies affected by hemolytic disease of the fetus and newborn (HDFN). It collects information to better understand the condition and improve care. You may join if you are pregnant with a history of a prior affected pregnancy and have a current antibody that could harm your baby.
This study tests a new, more detailed blood test to figure out your baby's blood type during pregnancy. This may help doctors better manage pregnancies affected by blood-type incompatibility and prevent hemolytic disease in newborns.
This Phase 3 trial tests nipocalimab (an antibody medicine) to help prevent severe blood breakdown in a baby when a parent has certain blood antibodies. It enrolls people who previously had severe hemolytic disease in a past pregnancy and who are currently early in pregnancy with the same risk antibodies.
This study tests a new blood test to track how the body responds to treatment during pregnancy, especially for those at risk of high blood pressure conditions. It may help doctors monitor and improve care.
This study tests whether giving regular blood transfusions during early pregnancy can help prevent complications for women with sickle cell disease. If you are between 6 and 20 weeks pregnant, you may join to see if this treatment improves outcomes.
Hear when a new Hemolytic Disease of the Newborn trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.